3D Printing of medicines, current and future challenges – Presented by Alvaro Goyanes, FabRx at The 3D Medicine & Pharmaceutical Printing Conference which will take place on Feb 01, 2017 at MECC Maastricht in The Netherlands.
3D printing (3DP) is an increasingly growing manufacturing technique that allows creating solid objects by deposition of layers.In the pharmaceutical field, 3DP may allow in the future the in situ fabrication of medicines with doses and drug combinations personalized to the patient. It is predicted a change from limited dose range formulations manufactured in industries to tailored-to-patient medicines prepared at the dispensing point.3DP includes several technologies, some of them already tested in pharmaceutics, e.g. fused-deposition modelling, powder bed inkjet printing or stereolithography. 3DP application in pharmacy will make necessary to adapt these technologies to the standards demanded and regulated by the pharmaceutical industry.
About Alvaro Goyanes
Alvaro is co-founder and Development Director at FabRx, a biotech company focused on developing 3D printing technology for fabrication of pharmaceuticals and medical devices. Previously, he was a Postdoctoral Researcher at University College London – School of Pharmacy, and he holds a PhD in Pharmaceutics from University of Santiago de Compostela (Spain). He has over 10 years’ experience in Pharmaceutics, and is passionate about technology and health.
FabRx is a specialist biotech company, focused on developing 3D printing technology for fabricating pharmaceuticals and medical devices. FabRx is a research-driven company and in addition to its IP portfolio, its members frequently publish research papers in peer-reviewed journals.